About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Use of Insulin Glargine to Treat Diabetic Ketoacidosis

NCT00179127·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Vanderbilt University Medical Center

Age

6–18

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Ages 6-18 y.o. presenting to Vanderbilt Children's Hospital (VCH) Emergency Room with:
Established history of insulin dependent diabetes
AND:
Chief c/o hyperglycemia or vomiting
Venous pH \< 7.24
Serum Bicarbonate \< 18
Blood glucose \> 150
Urinary Ketones

You may not be if

Age \< 6y.o.
New onset diabetes
Received IV insulin bolus prior to arrival to VCH Emergency Room (ER)
Venous pH \> 7.24
Serum Bicarbonate \> 18
Pregnancy
Received glargine within 12 hours prior to arrival to VCH Emergency Room/Pediatric Critical Care Unit

The record

StatusCompleted

PhaseNo phase

Taking part75

StartedAug 2004

UpdatedJul 16, 2018

Conditions

Diabetic Ketoacidosis

Where1

Vanderbilt University Monroe Carell Children's Hospital
Nashville, Tennessee, United States

Clareo Health | Use of Insulin Glargine to Treat Diabetic Ketoacidosis